ABBV - Galecto Finalizes Plan For $85 Million IPO October, 23 2020 05:34 PM AbbVie Inc. Galecto has filed proposed terms for an $85 million U.S. IPO. The firm is development treatments for various fibrosis diseases. GLTO has produced impressive trial results to-date. For life science investors with a long-term hold time frame, the IPO is worth considering. For further details see: Galecto Finalizes Plan For $85 Million IPO